Turn Therapeutics Updates Investor Presentation, Phase 2 AD Topline Due Q1 2027

Turn Therapeutics released an updated investor presentation detailing GX-03 clinical progress, with the Phase 2 topline readout anticipated in Q1 2027. The company reported a $10.3 million cash balance as of June 30, 2026, which provides runway into Q3 2027.